According to Boehringer Ingelheim, a combination of tiotropium and olodaterol delivered using the Respimat soft mist inhaler significantly improved 24-hour FEV1 in COPD patients compared to olodaterol monotherapy at all doses tested. The 4-week double-blind study with 232 COPD patients testing doses of tiotropium of 1.25, 2.5, and 5 μg with either 5 μg or 10 μg of olodaterol.
BI says that its Phase 2 program is now complete and that the Phase 3 TOviTO program has already begun.
The Phase 2 study’s lead author, René Aalbers of the Department of Pulmonology, Martini Hospital, Groningen, Netherlands, commented, “Combining two long-acting bronchodilators with different modes of action – the well established once-daily LAMAD tiotropium with olodaterol, an investigational and promising once-daily LABAE with a convincing 24-hour profile – has a complementary effect in the treatment of COPD patients. Olodaterol is an ideal partner to tiotropium due to its similar long-lasting effect at a low dose.”
Boehringer Ingelheim Corporate Senior VP of Medicine Klaus Dugi said, “Olodaterol, a once-daily LABA with a proven 24-hour profile in patients with COPD, has been designed by Boehringer Ingelheim as an ideal combination partner for tiotropium, the first once-daily inhaled long-acting anticholinergic bronchodilator to provide 24-hour bronchodilation in COPD. These new data give us confidence that we are moving closer to the fixed dose combination product of tiotropium and olodaterol, which could become a new treatment option for patients with COPD.”
Read the BI press release.
